Loading…
National Science and Technology Strategy Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
91pct
252d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
National Science and Technology Strategy Act of 2021 This bill requires the Office of Science and Technology Policy (OSTP) to develop a national science and technology strategy and publish a science and technology review. The bill revises OSTP reporting requirements to direct the OSTP to submit to Congress a comprehensive national science and technology strategy of the United States to meet national research and development objectives for the following four-year period. No later than December 31, 2022, and every four years afterwards, the OSTP shall complete a review of the science and technology enterprise of the United States.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2023 · second_quarter · Trade (domestic/foreign)
H.R. 3858: No Free TRIPS Act S. 1834: No Free TRIPS Act S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 (117th Congress) S. __: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $900,000 · Firm income: Not reported
Placed on the Union Calendar, Calendar No. 178.
Reported by the Committee on Science, Space, and Technology. H. Rept. 117-248.
Congress.gov source codes: 5000, H12200
Ordered to be Reported by Voice Vote.
Committee Consideration and Mark-up Session Held.
Referred to the House Committee on Science, Space, and Technology.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2023 · second_quarter · Trade (domestic/foreign)
H.R. 3858: No Free TRIPS Act S. 1834: No Free TRIPS Act S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 (117th Congress) S. __: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $6,300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| TX |
| Frank D. Lucas | Republican | OK |
| Jake Ellzey | Republican | TX |
| Jason Crow | Democratic | CO |